新型全自动电化学发光免疫分析法检测降钙素的多中心前瞻性验证研究
该研究在美国和欧洲9家转诊机构前瞻性验证新型电化学发光免疫分析法(ECLIA)检测血清降钙素(CT)的分析性能与临床价值,共纳入1929例受试者。结果显示该法空白限、检出限和定量限分别为0.3、0.5和1 ng/L,诊断灵敏度和特异性良好,健康人个体间变异低,钙刺激后2分钟达峰。
要点
- 新型ECLIA检测降钙素分析性能优异,功能灵敏度达1 ng/L。
- 健康女性/男性血清CT中位数分别为0.8和3 ng/L,97.5百分位为6.8和11.6 ng/L。
- 女性/男性诊断灵敏度100%/96.2%,特异性97.1%/96.4%。
核心结论
- 该新型ECLIA分析性能优异,个体间变异低,非甲状腺髓样癌患者中干扰因素影响小,具有合适的临床实用性。
- 钙刺激后CT结果个体间变异低,提示该检测适用性好。
研究设计与样本
- 多中心前瞻性研究,在美国和欧洲9家转诊机构检测基底血清CT浓度。
- 共纳入1929例患者和健康对照,另对50名健康志愿者静脉给予钙(2.5 mg/kg体重)后检测刺激后CT浓度。
主要发现
- ECLIA空白限、检出限和定量限分别为0.3、0.5和1 ng/L。
- 最高批内和批间变异系数分别为7.4%(CT浓度0.8 ng/L)和7.0%(1.1 ng/L)。
- 783名健康对照中,女性血清CT中位数0.8 ng/L(<0.5-12.7),男性3 ng/L(<0.5-18);97.5百分位分别为6.8和11.6 ng/L。
- 女性/男性诊断灵敏度和特异性分别为100%/97.1%和96.2%/96.4%。
- 原发性甲状旁腺功能亢进、肾衰竭和神经内分泌肿瘤患者(女/男)CT浓度超过97.5百分位的比例分别为33%/4.7%、18.5%/10%和8.3%/12%。
关键数值与推荐
- ECLIA空白限0.3 ng/L、检出限0.5 ng/L、定量限1 ng/L。
- 最高批内变异系数7.4%(0.8 ng/L),最高批间变异系数7.0%(1.1 ng/L)。
- 健康女性/男性CT的97.5百分位分别为6.8和11.6 ng/L。
- 女性/男性诊断灵敏度100%/96.2%,特异性97.1%/96.4%。
- 钙刺激后2分钟CT峰值男性161.7 ng/L、女性111.8 ng/L(P < 0.001)。
临床怎么用
- 该ECLIA可用于血清降钙素检测,具有低功能灵敏度(1 ng/L)和低个体间变异。
- 健康人参考区间应性别区分,女性97.5百分位6.8 ng/L,男性11.6 ng/L。
- 非甲状腺髓样癌疾病(如原发性甲状旁腺功能亢进、肾衰竭、神经内分泌肿瘤)可致CT升高,判读时需考虑。
- 钙刺激试验可行,2分钟时CT达峰,个体间变异低。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of this study is the validation and proof of clinical relevance of a novel electrochemiluminescence immunoassay (ECLIA) for the determination of serum calcitonin (CT) in patients with medullary thyroid carcinoma (MTC) and in different diseases of the thyroid and of calcium homeostasis. METHODS: This was a multicenter prospective study on basal serum CT concentrations performed in 9 US and European referral institutions. In addition, stimulated CT concentrations were measured in 50 healthy volunteers after intravenous calcium administration (2.5 mg/kg bodyweight). RESULTS: In total, 1929 patients and healthy controls were included. Limits of blank, detection, and quantification for the ECLIA were 0.3, 0.5, and 1 ng/L, respectively. Highest intra- and interassay coefficients of variation were 7.4% (CT concentration, 0.8 ng/L) and 7.0% (1.1 ng/L), respectively. Medians (interval) of serum CT concentrations in 783 healthy controls were 0.8 ng/L (<0.5-12.7) and 3 ng/L (<0.5-18) for females and males, respectively (97.5th percentile, 6.8 and 11.6 ng/L, respectively). Diagnostic sensitivity and specificity were 100%/97.1% and 96.2%/96.4%, for female/males, respectively. Patients (male/female) with primary hyperparathyroidism, renal failure, and neuroendocrine tumors showed CT concentrations >97.5th percentile in 33%/4.7%, 18.5%/10%, and 8.3%/12%, females/males, respectively. Peak serum CT concentrations were reached 2 min after calcium administration (161.7 and 111.8 ng/L in males and females, respectively; P < 0.001). CONCLUSIONS: Excellent analytical performance, low interindividual variability, and low impact of confounders for increased CT concentrations in non-MTC patients indicate that the investigated assay has appropriate clinical utility. Calcium-stimulated CT results suggest good test applicability owing to low interindividual variability.
引用
- Kahaly GJ, Algeciras-Schimnich A, Davis TE, et al. United States and European Multicenter Prospective Study for the Analytical Performance and Clinical Validation of a Novel Sensitive Fully Automated Immunoassay for Calcitonin. Clin Chem. 2017. PMID: 28687633. doi:10.1373/clinchem.2016.270009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。